SCHEDULE 13G/A: Dellora Investments and Kevin Pyun Disclose Continued Significant Stake in Tenax Therapeutics

Dellora Investments Master Fund LP, Dellora Investments LP, and Kevin Pyun have filed an amended Schedule 13G, disclosing their beneficial ownership of common stock in Tenax Therapeutics, Inc., with stakes reaching up to 8.8%.

Summary

• Dellora Investments Master Fund LP beneficially owns 305,257 shares of Tenax Therapeutics, Inc.'s common stock, representing 7.7% of the class.
• Dellora Investments LP and Kevin Pyun each beneficially own 351,071 shares of Tenax Therapeutics, Inc.'s common stock, representing 8.8% of the class.
• The ownership percentages are calculated based on 3,970,385 shares of common stock outstanding as of March 21, 2025, as reported by Tenax Therapeutics, Inc. in its Form 10-K.
• The reporting persons, Dellora Investments LP and Kevin Pyun, explicitly disclaim beneficial ownership over the reported securities, stating they were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain positive or negative operational or financial news. The continued significant stake by institutional investors could be seen as a neutral to slightly positive signal of confidence.

Positives

• The continued significant ownership by institutional investors like Dellora Investments and its principal, Kevin Pyun, may signal ongoing confidence in Tenax Therapeutics, Inc.'s long-term prospects.

Risks

• The document itself does not detail specific risks for Tenax Therapeutics, Inc. However, for the reporting entities, there is a concentration risk associated with holding a significant stake in a single issuer.

Future Outlook

NA

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "Dellora Investments LP and Mr. Pyun expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Dellora Investments LP or Mr. Pyun are the beneficial owner of any of the securities reported herein."

Industry Context

This filing is a routine disclosure of significant ownership by institutional investors in a publicly traded company. It does not provide specific industry trends or competitive analysis but indicates continued investor interest in the pharmaceutical sector, where Tenax Therapeutics operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Management: Awareness of significant shareholder interests, though the filing explicitly states no intent to influence control.

Next Steps

• The reporting persons will file further amendments to this Schedule 13G if there are material changes to their beneficial ownership of Tenax Therapeutics, Inc. common stock.

Key Dates

Keywords

Tenax Therapeutics, Dellora Investments, Kevin Pyun, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Investment Fund, Biotechnology, Pharmaceuticals